We confirmed the renoprotective effects of palonosetron by analysis of data from patients treated with cisplatin and aprepitant, an antagonist of tachykinin receptor 1 (TACR1, also known as neurokinin 1 receptor or substance P receptor) in clinical use as an antiemetic [30] for head and neck cancer, and we verified the in vivo efficacy of palonosetron in suppressing cisplatin-induced toxicity in zebrafish. This evidence concerns the gene TACR1 and head and neck cancer.